Cover Image
市場調查報告書

肌肉張力不全症:開發中產品分析

Dystonia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192569
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
肌肉張力不全症:開發中產品分析 Dystonia - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 45 Pages
簡介

肌肉張力不全症是指引起肌肉的不自主收縮及痙攣的運動障礙。會有運動時感到疼痛的情況,此外患者也有發抖或伴隨其他神經學性特徵的情況。症狀有引起反復性的運動或姿勢不正,壓力、疲勞或不安,及造成語言障礙的非自主性肌肉收縮。治療方法包含抗膽鹼促效劑及苯重氮基鹽。

本報告提供肌肉張力不全症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

肌肉張力不全症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • Addex Therapeutics Ltd
  • Advicenne Pharma
  • EpiVax, Inc.
  • Ipsen S.A.
  • Medy-Tox Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • abobotulinumtoxin A
  • abobotulinumtoxin A next generation
  • ADV-6979
  • dipraglurant ER
  • dipraglurant IR
  • onabotulinumtoxin A
  • onabotulinumtoxin A

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8556IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dystonia - Pipeline Review, H2 2016, provides an overview of the Dystonia (Central Nervous System) pipeline landscape.

Dystonia is a movement disorder that causes the muscles to contract and spasm involuntarily. The movements may be painful, and some individuals with dystonia may have a tremor or other neurologic features. Symptoms include involuntary muscle contractions that cause repetitive movements or distorted postures, stress, fatigue or anxiety and speech difficulties. Treatment includes anticholinergic and benzodiazepines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dystonia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dystonia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dystonia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dystonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Dystonia.

Dystonia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dystonia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dystonia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dystonia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dystonia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dystonia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dystonia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dystonia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dystonia Overview
  • Therapeutics Development
    • Pipeline Products for Dystonia - Overview
    • Pipeline Products for Dystonia - Comparative Analysis
  • Dystonia - Therapeutics under Development by Companies
  • Dystonia - Therapeutics under Investigation by Universities/Institutes
  • Dystonia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Dystonia - Products under Development by Companies
  • Dystonia - Products under Investigation by Universities/Institutes
  • Dystonia - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Advicenne SA
    • EpiVax, Inc.
    • Ipsen S.A.
    • Revance Therapeutics, Inc.
  • Dystonia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dipraglurant ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxinA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RT-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetrabenazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dystonia - Dormant Projects
  • Dystonia - Product Development Milestones
    • Featured News & Press Releases
      • Mar 05, 2016: Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology
      • Oct 29, 2015: Revance Reports Positive 6-Month Duration in BELMONT Study
      • Sep 29, 2015: Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia
      • Feb 26, 2007: Epivax Funded To Advance Research On A New, Improved "Botox"
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dystonia, H2 2016
  • Number of Products under Development for Dystonia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Dystonia - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Dystonia - Pipeline by Advicenne SA, H2 2016
  • Dystonia - Pipeline by EpiVax, Inc., H2 2016
  • Dystonia - Pipeline by Ipsen S.A., H2 2016
  • Dystonia - Pipeline by Revance Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dystonia - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Dystonia, H2 2016
  • Number of Products under Development for Dystonia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top